LCZ696 (sacubitril/valsartan) for patients with heart failure

Adrian V. Hernandez; Vinay Pasupuleti; Maciej Banach; Agata M. Bielecka-Dabrowa

doi:10.1002/14651858.CD013517

LCZ696 (sacubitril/valsartan) for patients with heart failure

Adrian V. Hernandez
, Vinay Pasupuleti
, Maciej Banach
, Agata M. Bielecka-Dabrowa

Producción científica: Contribución a una revista › Artículo › revisión exhaustiva

Resumen

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.

Idioma original	Inglés
Número de artículo	CD013517
Publicación	Cochrane Database of Systematic Reviews
Volumen	2020
N.º	1
DOI	https://doi.org/10.1002/14651858.CD013517
Estado	Publicada - 14 ene. 2020
Publicado de forma externa	Sí

Acceder al documento

10.1002/14651858.CD013517

Otros archivos y enlaces

Enlace a la publicación en Scopus

Citar esto

@article{711a4c3e452441aca2bc6e89d15c9fca,

title = "LCZ696 (sacubitril/valsartan) for patients with heart failure",

abstract = "This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.",

author = "Hernandez, \{Adrian V.\} and Vinay Pasupuleti and Maciej Banach and Bielecka-Dabrowa, \{Agata M.\}",

note = "Publisher Copyright: Copyright {\textcopyright} 2020 The Cochrane Collaboration. Published by John Wiley \& Sons, Ltd.",

year = "2020",

month = jan,

day = "14",

doi = "10.1002/14651858.CD013517",

language = "Ingl{\'e}s",

volume = "2020",

journal = "Cochrane Database of Systematic Reviews",

issn = "1465-1858",

publisher = "John Wiley and Sons Ltd",

number = "1",

}

TY - JOUR

T1 - LCZ696 (sacubitril/valsartan) for patients with heart failure

AU - Hernandez, Adrian V.

AU - Pasupuleti, Vinay

AU - Banach, Maciej

AU - Bielecka-Dabrowa, Agata M.

PY - 2020/1/14

Y1 - 2020/1/14

N2 - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.

AB - This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:. To assess benefits and harms of first-in-class angiotensin receptor-neprilysin inhibitor sacubitril/valsartan (LCZ696) as compared to angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) in chronic heart failure (HF) patients with either reduced, mid-range, or preserved ejection fraction.

UR - https://www.scopus.com/pages/publications/85088244906

U2 - 10.1002/14651858.CD013517

DO - 10.1002/14651858.CD013517

M3 - Artículo

AN - SCOPUS:85088244906

SN - 1465-1858

VL - 2020

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 1

M1 - CD013517

ER -

LCZ696 (sacubitril/valsartan) for patients with heart failure

Resumen

Acceder al documento

Otros archivos y enlaces

Huella

Citar esto